Arrhythmogenic Cardiomyopathy: Exercise Pitfalls, Role of Connexin-43, and Moving beyond Antiarrhythmics

Area of Science:

• Cardiology
• Genetics
• Molecular Biology

Background:

• Arrhythmogenic Cardiomyopathy (ACM) is a genetic heart condition characterized by fibrofatty myocardial replacement.
• Current ACM therapies aim to prevent disease progression and sudden cardiac death (SCD), but cannot restore electrical signal propagation disrupted by fibrosis.
• Patients with ACM often exhibit reduced levels of Connexin-43 (Cx43) at the myocyte intercalated disc.

Purpose of the Study:

• To investigate the potential of increasing Connexin-43 (Cx43) expression to ameliorate cardiac electrical conduction abnormalities in Arrhythmogenic Cardiomyopathy (ACM).
• To explore exercise and gene therapy as potential strategies for enhancing Cx43 levels in ACM.
• To address the translational gap between current ACM therapeutic limitations and potential novel interventions.

Main Methods:

• Review of recent studies on exercise effects on Cx43 expression in healthy and diseased mice.
• Analysis of Cx43 expression levels in ACM patients and its correlation with disease phenotype.
• Exploration of low-to-moderate intensity exercise and gene therapy as potential modulators of Cx43.

Main Results:

• Exercised mice demonstrated increased Connexin-43 (Cx43) expression.
• Elevated Cx43 levels were shown to improve abnormal electrical signal conduction in the myocardium of diseased mice.
• ACM patients exhibit reduced Cx43 levels, contributing to impaired electrical signal propagation.

Conclusions:

• Increased Cx43 expression, potentially through low-to-moderate exercise or gene therapy, could improve cardiac function in ACM patients.
• Targeting Cx43 offers a promising therapeutic avenue to mitigate electrical conduction defects in ACM.
• Current ACM treatment guidelines advising exercise cessation may exacerbate disease progression by limiting Cx43 upregulation.